Journal for ImmunoTherapy of Cancer: 5 (1)

Basic Tumor Immunology

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment (19 December, 2017)
Susanne M. Steggerda, Mark K. Bennett, Jason Chen, Ethan Emberley, Tony Huang, Julie R. Janes, Weiqun Li, Andrew L. MacKinnon, Amani Makkouk, Gisele Marguier, Peter J. Murray, Silinda Neou, Alison Pan, Francesco Parlati, Mirna L. M. Rodriguez, Lee-Ann Van de Velde, Tracy Wang, Melissa Works, Jing Zhang, Winter Zhang, Matthew I. Gross
Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer (15 August, 2017)
Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward, Sarah L. Young
Tumor-derived exosomes induce CD8⁺ T cell suppressors (15 August, 2017)
Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero, Brian R. Gastman
Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy (15 August, 2017)
Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan, Samir N. Khleif
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment (15 August, 2017)
Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart, Robert W. Wilkinson
Adoptive cell therapy using PD-1⁺ myeloma-reactive T cells eliminates established myeloma in mice (20 June, 2017)
Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese, Bryon D. Johnson
GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory (20 June, 2017)
Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow, Scott H. Robbins
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines (16 May, 2017)
Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic, Rimas J. Orentas
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation (21 February, 2017)
Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka, Craig T. Morita

Case Report

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma (19 December, 2017)
Pouyan N. Changizzadeh, Shiva Kumar R. Mukkamalla, Vincent A. Armenio
Smoldering myocarditis following immune checkpoint blockade (21 November, 2017)
Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi, Robert M. Conry
Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection? (21 November, 2017)
Gustavo dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes, Renata de Almeida Coudry
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden (19 September, 2017)
Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal, David Jablons
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (15 August, 2017)
Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott, Toni K. Choueiri
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition (15 August, 2017)
Quaovi Sodji, Kandy Klein, Kavuri Sravan, Jigarkumar Parikh
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab (18 July, 2017)
Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon, Patrick A. Ott
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes (18 July, 2017)
Michael C. Topf, Madalina Tuluc, Larry A. Harshyne, Adam Luginbuhl
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report (18 July, 2017)
Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride, Andrew S. Kraft
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma (18 July, 2017)
Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas, Stephane Dalle
Progressive hypoventilation due to mixed CD8⁺ and CD4⁺ lymphocytic polymyositis following tremelimumab - durvalumab treatment (18 July, 2017)
Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner, Ben C. Creelan
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy (20 June, 2017)
Jose D. Sandoval-Sus, Francis Mogollon-Duffo, Ankita Patel, Nathan Visweshwar, Damian A. Laber, Richard Kim, Michael V. Jagal
Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade (20 June, 2017)
Heinz Läubli, Jürgen Hench, Michal Stanczak, Ingmar Heijnen, Alexandros Papachristofilou, Stephan Frank, Alfred Zippelius, Frank Stenner-Liewen
Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma (20 June, 2017)
Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers, Hussein Tawbi
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer (16 May, 2017)
James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra, Colleen Veloski
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone (18 April, 2017)
Samuel Rosner, Filiz Sen, Michael Postow
Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients (18 April, 2017)
Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot, Karim Fizazi
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP) (21 March, 2017)
Jeanelle King, Javier de la Cruz, Jose Lutzky
Immunotherapy-associated autoimmune hemolytic anemia (21 February, 2017)
Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka, Tarik Hadid
Nivolumab induced myxedema crisis (21 February, 2017)
Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu, Tarik Hadid
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation (21 February, 2017)
James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek, Justin Kline
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy (21 February, 2017)
Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu, Douglas Johnson
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma (17 January, 2017)
Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell, Douglas B. Johnson
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor (17 January, 2017)
Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka, Jose Lutzky

Clinical/Translational Cancer Immunotherapy

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer (19 December, 2017)
Rachel E. Sanborn, Helen J. Ross, Sandra Aung, Anupama Acheson, Tarsem Moudgil, Sachin Puri, Traci Hilton, Brenda Fisher, Todd Coffey, Christopher Paustian, Michael Neuberger, Edwin Walker, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM^SM registry (19 December, 2017)
Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials (19 December, 2017)
Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam, Vivek Subbiah
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas (19 December, 2017)
Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky, Christian Grommes
Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial (19 December, 2017)
Robert J. Canter, Steven K. Grossenbacher, Jennifer A. Foltz, Ian R. Sturgill, Jiwon S. Park, Jesus I. Luna, Michael S. Kent, William T. N. Culp, Mingyi Chen, Jaime F. Modiano, Arta M. Monjazeb, Dean A. Lee, William J. Murphy
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer (21 November, 2017)
Zachary J. Brown, Bernd Heinrich, Seth M. Steinberg, Su Jong Yu, Tim F. Greten
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer (21 November, 2017)
Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall, Craig L. Slingluff
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma (21 November, 2017)
Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz, Wilson H. Miller
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment (17 October, 2017)
Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada, Kathryn Beal
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute (19 September, 2017)
Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood, Hussein A. Tawbi
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma (19 September, 2017)
Veronika Kremer, Marteen A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell, Andreas Lundqvist
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials (19 September, 2017)
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection (19 September, 2017)
Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo, Kerry Fisher
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC (19 September, 2017)
Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama, Xavier Préville
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma (20 June, 2017)
Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling, Alex Karlsson-Parra
Evaluation of dosing strategy for pembrolizumab for oncology indications (16 May, 2017)
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer (18 April, 2017)
Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez, Constantin N. Baxevanis
Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors (18 April, 2017)
Robert Aguilar, Justin M. Johnson, Patrick Barrett, Vincent K. Tuohy
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies (18 April, 2017)
Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma, James Allison, Funda Meric-Bernstam, David S. Hong
Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death (18 April, 2017)
Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge, Darrin Uecker
A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood (18 April, 2017)
Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson, Allan B. Dietz
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy (21 March, 2017)
Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman, Xiuli Wang
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer (21 March, 2017)
Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June, Stephen A. Sherwin
CCR7⁺ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo (21 February, 2017)
Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins, David Edward Gilham
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen (17 January, 2017)
Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur, Philippe Slos

Commentary

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis? (19 December, 2017)
Roger Sun, Francois-Xavier Danlos, Samy Ammari, Guillaume Louvel, Frédéric Dhermain, Stéphane Champiat, Olivier Lambotte, Eric Deutsch
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap (18 July, 2017)
Frederick L. Locke, Claudio Anasetti, for the Moffitt Immunotherapy Working Group and the Immune Cell Therapy (ICE-T) Program
Tissue-resident lymphocytes: sentinel of the transformed tissue (16 May, 2017)
Saïda Dadi, Ming O. Li
The why, what, and how of the new FACT standards for immune effector cells (18 April, 2017)
Marcela V. Maus, Sarah Nikiforow
Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis (21 March, 2017)
Marc-Elie Nader, Matthew Zibelman, Jeffrey N. Myers, Paul W. Gidley, Natasha Pollak, Anthony J. Olszanski
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer (21 February, 2017)
Stefan N. Symeonides, Stephen M. Anderton, Alan Serrels
Immunotherapy resistance: the answers lie ahead – not in front – of us (21 February, 2017)
Miles C. Andrews, Jennifer A. Wargo
It’s a long way to the top (if you want to personalize immunotherapy) (17 January, 2017)
Sarah Haebe, Oliver Weigert
Potassium channels of T lymphocytes take center stage in the fight against cancer (17 January, 2017)
Laura Conforti

Immunotherapy Biomarkers

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response (21 November, 2017)
Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim, Jing Zhou
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy (17 October, 2017)
Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana, Ulka Vaishampayan
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer (17 October, 2017)
Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper, David L. Rimm
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab (15 August, 2017)
Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj, William K. Oh
Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination (18 July, 2017)
Laura E. Johnson, Brian M. Olson, Douglas G. McNeel
Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy (18 April, 2017)
Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb, William J. Murphy
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma (21 March, 2017)
James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger, David L. Rimm
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody (21 February, 2017)
Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley, Jeffrey Schlom
Gene expression markers of Tumor Infiltrating Leukocytes (21 February, 2017)
Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem, Steven P. Fling

Meeting Report

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer (19 September, 2017)
Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong, Marcus W. Bosenberg
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31^st Anniversary Annual Meeting (18 April, 2017)
Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu
Immunotherapy biomarkers 2016: overcoming the barriers (21 March, 2017)
James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger, Janet Siebert, David F. Stroncek, Magdalena Thurin, Jianda Yuan, Lisa H. Butterfield

Position Articles and Guidelines

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (21 November, 2017)
I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman, M. S. Ernstoff, on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group , Jeff Anderson, Deborah Arrindell, Stephanie Andrews, Joan Ballesteros, Janie Boyer, Daniel Chen, David Chonzi, Ion Cotarla, Renato Cunha, Marianne Davies, Michelle Dawson, Adam Dicker, Lisa Eifler, Andrew Ferguson, Cristiano Ferlini, Stanley Frankel, William Go, Celestine Gochett, Jenna Goldberg, Priscila Goncalves, Trishna Goswami, Nancy Gregory, James L. Gulley, Vinny Hayreh, Nicole Helie, William Holmes, Jer-Yuan Hsu, Ramy Ibrahim, Cecilia Larocca, Kimberly Lehman, Sergio Ley-Acosta, Olivier Lambotte, Jason Luke, Joan McClure, Elisabete Michelon, Mary Nakamura, Kiran Patel, Bilal Piperdi, Zeshaan Rasheed, Dan Reshef, Joanne Riemer, Caroline Robert, Makan Sarkeshik, Ann Saylors, Judy Schreiber, Kim Shafer-Weaver, William Sharfman, Elad Sharon, Richard Sherry, Cyndy Simonson, Cherry Thomas, John A. Thompson, Elizabeth Trehu, Dina Tresnan, Michelle Turner, Darshan Wariabharaj, Ian Waxman, Lauren Wood, Lin Zhang, Pan Zheng
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (15 August, 2017)
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg

Review

Biomarkers for immunotherapy in bladder cancer: a moving target (21 November, 2017)
David H. Aggen, Charles G. Drake
Prospects for combined use of oncolytic viruses and CAR T-cells (21 November, 2017)
Adam Ajina, John Maher
The immune system in cancer metastasis: friend or foe? (17 October, 2017)
Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon, Willem W. Overwijk
Immuno-thermal ablations – boosting the anticancer immune response (17 October, 2017)
Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst, Hyun S. Kim
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016 (18 July, 2017)
James L. Gulley, Elizabeth A. Repasky, Laura S. Wood, Lisa H. Butterfield
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy (18 July, 2017)
Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries, Dominik Rüttinger
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 (20 June, 2017)
Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky, Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey, Charles G. Drake, Gordon J. Freeman, Ramy Ibrahim, Salil Patel, Daniel S. Chen
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (16 May, 2017)
Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton, Lisa H. Butterfield
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment (21 March, 2017)
Irene Scarfò, Marcela V. Maus
Systematic evaluation of immune regulation and modulation (21 March, 2017)
David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri, Barbara Seliger
Combination immunotherapy: a road map (21 February, 2017)
Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok
Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer (17 January, 2017)
Juan R. Cubillos-Ruiz, Eslam Mohamed, Paulo C. Rodriguez

Short Report

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade (21 March, 2017)
Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Schollenberger, William H. Sharfman, Janis M. Taube

Erratum

Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma (6 November, 2017)
Veronika Kremer, Maarten A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell, Andreas Lundqvist
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (28 September, 2017)
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer (30 May, 2017)
Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez, Constantin N. Baxevanis
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab (6 March, 2017)
Frances M. Walocko, Benjamin Y. Scheier, Paul W. Harms, Leslie A. Fecher, Christopher D. Lao
Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 (18 January, 2017)
Marc Uemura, Faisal Fa’ak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff, Adi Diab

Main menu

Table of contents

December 2017 - Volume 5 - 1

Basic Tumor Immunology

Case Report

Clinical/Translational Cancer Immunotherapy

Commentary

Immunotherapy Biomarkers

Meeting Report

Position Articles and Guidelines

Review

Short Report

Erratum

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

December 2017 - Volume 5 - 1

Basic Tumor Immunology

Case Report

Clinical/Translational Cancer Immunotherapy

Commentary

Immunotherapy Biomarkers

Meeting Report

Position Articles and Guidelines

Review

Short Report

Erratum